deepeye Medical GmbH

We will prevent 1m additional people from blindness by 2030 by empowering eye doctors with AI-based optimal therapy prognosis.

We were profitable in our first year. Our pre-clinical AI is used by pharma, payors and providers’ associations (0.44m€ sales). With 1.5m€ in pre-orders, we work on our clinical product to provide therapy decision support with 1 click at the PoC in 2024. For this, we currently raise 2m€, of which the majority is already committed.

100m people globally suffer from vision-threatening retinal diseases. A $13bn drug can stop patients from vision loss. Still, ⅔ of cases of blindness in EU+US are due to these diseases. Our precision medicine platform improves therapy by up to 6x by boosting:
- Adherence & persistence from 38% to 78% (2x)
- Real-world vision outcomes from 36% to 100% (3x)

The deepeye® Suite is a precision medicine platform for retinal therapy: https://youtu.be/dNi3Ut_Za_8?t=64

Impossible to copy is our core IP, the unique dataset our AI is trained on: 0.5+m proprietary OCT scans + structured, clinical data from 65+ eye centers.

We sell annual licenses (SaaS) to retina specialists (1st customer) but also to pharma and general ophthalmologists (2nd customer), while harvesting data from both (2-sided market model). Our ultimate goal is reimbursement also in the US and maybe patient revenue for therapy reports.

https://eithealth.eu/programmes/gold-track/